Current Edition


With Merck’s oral COVID-19 med molnupiravir set for authorization, U.S. spends another $1B for 1.4 million courses

With molnupiravir, Merck & Co. and Ridgeback’s oral treatment for COVID-19, apparently on the doorstep of authorization, the U.S. has moved to secure additional doses …

Continue Reading →
antiviral molnupiravir

Merck and Ridgeback’s molnupiravir will be ‘complementary, but not a competitor’ to COVID-19 vaccines: analyst

What do Merck and Ridgeback’s eye-opening data, recently released for its antiviral molnupiravir on high-risk COVID-19 patients, mean for manufacturers of vaccines? Analysts from the …

Continue Reading →